Inovio Pharmaceuticals is easily one of the most volatile stocks on the market right now. Vice President, Biological Manufacturing and Clinical Supply Management, Senior Vice President, Regulatory Affairs, Senior Vice President, Engineering Development, INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020, INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800, INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium. We know that patients are waiting.”, PRAKASH BHUYAN, M.D., Ph.D.Vice President, Clinical Development, “A virus cannot be cut out by a scalpel. Market data powered by FactSet and Web Financial Group. This includes candidates treating viruses (including HIV, Ebola, Middle East Respiratory Syndrome, Zika), prostate cancer, head and neck cancer, and glioblastoma (an aggressive form of brain cancer). Market data powered by FactSet and Web Financial Group. Copyright, Trademark and Patent Information. On the other hand, Inovio already has experience in developing a vaccine against a very similar virus, MERS. With only $89.5 million on its balance sheet -- less than three quarters worth of financing at the current rate of expenditures -- the company doesn't have much financial breathing room. endstream endobj startxref �/�b�wwS�N�cLe�u3�]GA��� w6ܯ�iF �0 !�� Its main rival in the COVID-19 vaccine market is Moderna (NASDAQ:MRNA), which is developing an mRNA-based vaccine for the virus. %%EOF If you’re unfamiliar, Theranos was a … The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. See you at the top! L:�I0� &M�����`]j �����?�`�� ��/����@�m �p���lB����� 2e1��+�������l� ���� �>� All rights reserved. Although still highly experimental, these types of treatments are supposed to be faster and more efficient than their DNA-based counterparts. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Citron Research produces research reports on publicly traded securities, and Citron Capital is an exempt reporting adviser filed with the California Department of Business Oversight. The biotech company sent out a tweet of its own to reassure investors, dismissing Citron Research as a third-party that had "demonstrated a lack of understanding of the science behind DNA medicines." Inovio down 5% as Citron Research sees over 80% downside risk Sep. 29, 2020 2:38 PM ET | About: Inovio Pharmaceuticals... (INO) | By: Douglas W. House , SA News Editor �������d1X}:��LV�E��ٞ`��`���5��ˮ����l0�DV\���@�����Dj� ��86�D���H��H-����� �c� �L�g`�~` ��� Net losses, as expected, were quite high, coming in at $37.7 million. h�b```�]��w�@(������� �ڔI��fs8u��;00�S�8ZxN$�$^p�r=r�L��������;%�M��r�����7k�� e�$�Ŧ'��,��$`� ��r?�8�|A��h`RRq����+�4��X:L���(��Du'�l��@Z���"��KY�2|ale4d�c2b����4�I����mLnLU|S������gPpw���,����_(��C�qc;�8�5��E���1���{!<4$�v?Ҍ@` 9�V6 © Copyright 2020 INOVIO Pharmaceuticals. endstream endobj startxref INO-4700 is currently in phase 2 trials against MERS and has shown to be effective so far. This would suggest that Moderna's candidate has the edge over Inovio's. Stock Advisor launched in February of 2002. Inovio's INO-4800 is a traditional DNA-based vaccine, while Moderna's candidate, mRNA-1273, is an mRNA-based treatment. See you at the top! Inovio Pharmaceuticals (NASDAQ:INO) has been one of the hottest biotech stocks on the market, with shares continuing to see dramatic price swings in both directions as the COVID-19 pandemic continues to spread. Copyright, Trademark and Patent Information. Currently, VGX-3100 is undergoing one phase 3 and two phase 2 trials, with results expected this year. Since then, Inovio's been one of the hottest coronavirus stocks on the market. Although there's a lot of excitement surrounding this company, Inovio has its fair share of critics, including one of the most well-known short-seller outfits, Citron Research. However, even after that sharp decline, the company's shares are up by 140% year to date, which compares quite favorably to the S&P 500's 13.6% loss thus far in 2020. In April, Citron Research issued a scathing report calling Inovio the Theranos of COVID-19 vaccine development. Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines? Although both companies are working on a vaccine, the underlying methodology behind how they work is different. endstream endobj 165 0 obj <. However, Moderna's treatment is still experimental, with this COVID-19 vaccine being the first time that the company has tried to treat a virus of this type. 221 0 obj <>stream Additional organizations, such as the Bill and Melinda Gates Foundation, have also made contributions to Inovio to help accelerate the development of a delivery system for the company's COVID-19 vaccine, INO-4800. endstream endobj 443 0 obj <. While there's a lot of potential upside to Inovio, I think it's just too volatile to recommend for most investors at the moment. Inovio says it still plans to start human clinical trials of INO-4800 in the U.S. in April. h�b```�����B cc`a��q��Ǒ����c.�s��w(��ҵ��caksp�a`8�셓Ȕ���E��$�糰ܶ�NKˮf��%��LM������ᘬJh��۩��g%>^�l���V�QG�T0H��9 @�Ϻ�ψ��:+ �ul2� t��hzy ���1X����B�W@hq-h�Cu Y�0�PT�p:��V@`����3�Vb%�� �B֯_[f1�211|a��������I���1�Y��#��s�5~L�s�v�6 499 0 obj <>stream This delivery has enabled us to overcome a key limitation of other DNA and other nucleic acid approaches, such as mRNA.”, MARK TWYMAN, MBAVice President, Commercial, “The goal of our DNA medicines is to redefine success in the treatment of HPV-related diseases, as well as other infectious diseases, and cancers. %%EOF A bigger threat to Inovio comes from potential competitors. However, Citron Research singled out Inovio on Monday, claiming that the biotech company should be investigated by the Securities and Exchange Commission (SEC) for some of these claims.
Marvel Argumentative Essay Topics, Amirah Vann Kids, Sweet Flag Lifespan, Klondike Solitaire Gratuit Plein écran, Discours Pour Honorer Un Pasteur,